Neurological - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Glioma

Glioma
Protocol Administration at chemotherapy unit level Review Date
Anaplastic glioma PCV (procarbazine lomustine vinCRISTine) Medium August 2025
Anaplastic glioma temozolomide following radiation Low August 2023
Glioblastoma recurrent bevacizumab Low August 2023
Glioblastoma recurrent lomustine Low August 2023
Glioblastoma temozolomide chemoradiation (part 1) Low February 2023
Glioblastoma temozolomide following chemoradiation (part 2) Low February 2023
Glioblastoma temozolomide following short course chemoradiation (elderly patients) (part 2) Low February 2023
Glioblastoma temozolomide short course chemoradiation (elderly patients) (part 1) Low August 2023
Glioma high grade or recurrent temozolomide Low February 2023
Glioma high grade recurrent PCV (procarbazine lomustine vinCRISTine) Medium August 2023
Glioma low grade PCV (procarbazine lomustine vinCRISTine) Medium August 2023

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.